Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27kip1

Blood

Volumn 98, Issue 5, 2001, Pages 1524-1531

  Barata, Joao T ^a   Cardoso, Angelo A ^a   Nadler, Lee M ^a   Boussiotis, Vassiliki A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; INTERLEUKIN 7; PROTEIN BCL 2; PROTEIN P27;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL MATURATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; T CELL LEUKEMIA;

EID: 0035469821     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.5.1524     Document Type: Article

References (52)

1. Rich BE, Campos-Torres J, Tepper RI, Moreadith RW, Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med. 1993;177:305-316.
2. Peschon JJ, Morrissey PJ, Grabstein KH, et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med. 1994;180:1955-1960.
3. Akashi K, Kondo M, von Freeden-Jeffry U, Murray R, Weissman IL. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell. 1997;89:1033-1041.
4. -/- mice. Cell. 1997;89:1011-1019.
5. von Freeden-Jeffry U, Vieira P, Lucian LA, McNeil T, Burdach SEG, Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med. 1995;181:1519-1526.
6. von Freeden-Jeffry U, Solvanson N, Howard M, Murray R. The earliest T lineage-committed cells depend on IL-7 for bcl-2 expression and normal cell cycle progression. Immunity. 1997;7:147-154.
7. Touw I, Pouwels K, van Agthoven T, et al. Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood. 1990;75:2097-2101.
8. Makrynikola V, Kabral A, Bradstock K. Effects of interleukin 7 on the growth of clonogenic cells in T-cell acute lymphoblastic leukemia. Leukemia Res. 1991;15:879-882.
9. Karawajew L, Ruppert V, Wuchter C, et al. Inhibition of in vivo spontaneous apoptosis by IL-7 correlates with Bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. Blood. 2000;96:297-306.
10. Cardoso AA, Schultze JL, Boussiotis VA, et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 1996;88:41-48.
11. Boussiotis VA, Lee BJ, Freeman GJ, Gribben JG, Nadler LM. Induction of T cell clonal anergy results in resistance, whereas CD28 mediated costimulation primes for susceptibility to Fas and Bax mediated programmed cell death. J Immunol. 1997;159:3156-3167.
12. Donovan J, Ladetto M, Neuberg D, Poor C, Bowere D, Gribben JG. Immunoglobulin heavy-chain consensus probes for real time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood. 1998;95:2651-2658.
13. Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM. Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science. 1997;278:124-128.
14. Matsushime H, Quekke DE, Shurtleff SA, Shibuya M, Sheer CJ, Kato JY. D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol. 1994;14:2066-2076.
15. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell. 1997;88:223-233.
16. kip1 functions as an anergy factor inhibiting IL-2 transcription and clonal expansion of alloreactive human and murine helper T lymphocytes. Nat Med. 2000;6:551-555.
17. Uckun FM, Gayton PS, Sensel MG, et al. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturation stage of T-lineage leukemic blasts: a children's cancer group study. J Clin Oncol. 1997;15:2214-2221.
18. Akashi K, Kondo M, Weissman IL. Role of interleukin-7 in T-cell development from hematopoietic stem cells. Immunol Rev. 1998;165:13-28.
19. Sherr CJ. G1 phase progression: cyclin on cue. Cell. 1994;79:551-555.
20. Weintraub SJ, Prater CA, Dean DC. Retinoblastoma protein switches the E2F site from positive to negative element. Nature. 1992;358:259-261.
21. DeCaprio JA, Fukurawa T, Ajchenbaum F, Griffin JD, Livingston DM. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad Sci U S A. 1992;89:1795-1798.
22. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-330.
23. Morice WG, Wiederrecht G, Brunn GJ, Siekierka JJ, Abraham RT. Rapamycin inhibition of interleukin-s-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes. J Biol Chem. 1993;268:22737-22745.
24. kip1 cyclindependent kinase inhibitor prevented by rapamycin. Nature. 1994;372:570-573.
25. Henney CS. Interleukin 7: effects on early events in lymphopoiesis. Immunol Today. 1989;10:170-174.
26. Kim K, Lee C-K, Sayers TJ, Muegge K, Durum SK. The trophic action of IL-7 on pro-T cells: inhibition of apoptosis of pro-T1, -T2 and -T3 cells correlates with Bcl-2 and Bax levels and is independent of Fas and p53 pathways. J Immunol. 1998;160:5735-5741.
27. Hare KJ, Jenkison EJ, Anderson G. An essential role for the IL-7 receptor during intrathymic expansion of the positively selected neonatal T cell repertoire. J Immunol. 2000;165:2410-2414.
28. + severe combined immunodeficiency. Nat Genet. 1998;20:394-397.
29. Roifman CM, Zhang J, Chitayat D, Sharfe N. A partial deficiency of interleukin-7Ra is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood. 2000;96:2803-2807.
30. Hofmeister R, Khaled R, Benbernou N, Rajnavolgyi E, Muegge K, Durum SK. Interleukin-7: physiological roles and mechanisms of action. Cytokine Growth Factor Rev. 1999;10:41-60.
31. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440-442.
32. Fairbairn LJ, Cowling GJ, Reipert BM, Dexter TM. Suppression of apoptosis allows differentiation and development of a multipotent hemopoietic cell line in the absence of added growth factors. Cell. 1993;74:823-832.
33. Mazel S, Burtrum D, Petrie HT. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J Exp Med. 1996;183:2219-2226.
34. Vairo G, Soons TJ, Upton TM, et al. Bcl-2 retards cell cycle entry through p27kip1, pRb relative p130, and altered E2F regulation. Mol Cell Biol. 2000;20:4745-4753.
35. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995;9:1149-1163.
36. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haploinsufficient for tumour suppression. Nature. 1998;396:177-180.
37. St Croix B, Florenes VA, Rak JW, et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med. 1996;2:1204-1210.
38. kip1 protein: prognostic implications in primary breast cancer. Nat Med. 1997;3:227-230.
39. Dibirdik I, Langlie M-C, Ledbetter JA, et al. Engagement of interleukin-7 receptor stimulates tyrosine phosphorylation, phosphoinositide turnover, and clonal proliferation of human T-lineage acute lymphoblastic leukemia cells. Blood. 1991;78:546-570.
40. Ihle JN, Kerr IM. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 1995;11:69-74.
41. Kashii Y, Uchida M, Kirito K, et al. A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. Blood. 2000;96:941-949.
42. Hengst L, Reed SI. Translational control of p27kip1 accumulation during the cell cycle. Science. 1996;271:1861-1864.
43. Pagano M, Tam SW, Theodoras AM, et al. Role of ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;269:682-685.
44. Appleman LJ, Baerezovskaya A, Grass I, Boussiotis VA. CD28 costimulation mediates T cell expansion via IL-2 independent and IL-2 dependent regulation of cell cycle progression. J Immunol. 2000;164:144-151.
45. kip1. Nature. 2000;404:782-787.
46. kip1. Mol Cell Biol. 2000;20:9138-9148.
47. kip1 expression. Mol Cell Biol. 1998;18:1996-2003.
48. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27kip1. EMBO J. 1997;17:5334-5344.
49. kiP1. Genes Dev. 1997;11:1468-1478.
50. Takuwa N, Takuwa Y. Ras activity in G1 phase required for p27kip1 downregulation, passage through the restriction point and entry into S phase in growth factor-stimulated NIH-3T3 fibroblasts. Mol Cell Immunol. 1997;17:5348-5358.
51. Ihle JN. Cytokine receptor signalling. Nature. 1995;377:591-594.
52. Sherr CJ. The Pezcoller Lecture: Cancer cell cycles revisited. Cancer Res. 2000;60:3689-3695.